The Journal of the Pharmacy Society of Wisconsin
  • Home
  • Past Issues
    • Journal Archives
    • JPSW 2023
    • JPSW 2022
    • JPSW 2021
    • JPSW 2020
    • JPSW 2019
    • JPSW 2018
    • JPSW 2017
  • JPSW Supplements
  • For Authors and Reviewers
    • Author Guidelines
    • CE Author Guidelines
    • Case Report Author Guidelines
    • Types of Manuscripts
    • Peer Review Information
    • Emerging Writers Course
    • Editorial Plans
    • Submit a Manuscript
  • Open-Access Series
    • Preceptor Development Series
    • Statistics Review Series
  • About
    • Advertise in The Journal
    • Editorial Advisory Committee
  • Contact

Novel Antihyperglycemics and their Uses in Type 2 Diabetes Mellitus and Beyond.

by Zabrina Y.O. Abolarin, BS, 2024 PharmD Candidate, Angelica DiPrizio, BS, 2023 PharmD Candidate, Jessica R. Schwartzwald, BS, 2024 PharmD Candidate, Dagmara P. Zajac, BS, 2023 PharmD Candidate 

"While United States guidelines for the treatment of type 2 diabetes mellitus (T2DM) have not undergone a major change in the most recent update, the number of treatments and the amount of research into novel approaches are in constant flux. Currently, there are 11 antihyperglycemic classes used in the treatment of T2DM. The newer SGLT-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), adjunct to lifestyle modifications, help reduce hemoglobin A1c and maintain glycemic control; however, recent investigations for their use beyond T2DM have earned them a place in the treatment of heart failure, chronic kidney disease, and obesity management." 


​
Keywords: Empagliflozin, Dapagliflozin, Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Canagliflozin, Glycated Hemoglobin A, Glucagon-Like Peptide-1 Receptor, Ertugliflozin, Creatinine, Liraglutide, Cardiovascular Diseases, Blood Pressure, Semaglutide, Arterioles, Diabetic Nephropathies, Fasciitis, Necrotizing, Glomerular Filtration Rate, Glycemic Control, Hyperkalemia, Insulin Resistance, Natriuresis, United States Food and Drug Administration, Urine, Risk Factors, Clinical Protocols, Hospitalization, Dyslipidemias, Hypoglycemia, Amputation, Retinal Diseases, Glucose, Obesity

​Download PDF 

2022 September/October Table of Contents 

The Journal of the Pharmacy Society of Wisconsin


Past Issues

2020
2021
​2022
2019
2018
2017

About PSW

www.pswi.org

Contact Us

thejournal@pswi.org
  • Home
  • Past Issues
    • Journal Archives
    • JPSW 2023
    • JPSW 2022
    • JPSW 2021
    • JPSW 2020
    • JPSW 2019
    • JPSW 2018
    • JPSW 2017
  • JPSW Supplements
  • For Authors and Reviewers
    • Author Guidelines
    • CE Author Guidelines
    • Case Report Author Guidelines
    • Types of Manuscripts
    • Peer Review Information
    • Emerging Writers Course
    • Editorial Plans
    • Submit a Manuscript
  • Open-Access Series
    • Preceptor Development Series
    • Statistics Review Series
  • About
    • Advertise in The Journal
    • Editorial Advisory Committee
  • Contact